Cambridge Trust Co. Sells 17,571 Shares of CVS Health Co. (NYSE:CVS)

Cambridge Trust Co. decreased its holdings in shares of CVS Health Co. (NYSE:CVS) by 32.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,045 shares of the pharmacy operator’s stock after selling 17,571 shares during the quarter. Cambridge Trust Co.’s holdings in CVS Health were worth $2,925,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. NBW Capital LLC acquired a new stake in CVS Health during the 4th quarter valued at $206,000. Twin Capital Management Inc. lifted its holdings in CVS Health by 18.2% during the 4th quarter. Twin Capital Management Inc. now owns 34,662 shares of the pharmacy operator’s stock valued at $2,737,000 after purchasing an additional 5,335 shares during the last quarter. HF Advisory Group LLC lifted its holdings in CVS Health by 35.4% during the 4th quarter. HF Advisory Group LLC now owns 13,926 shares of the pharmacy operator’s stock valued at $1,100,000 after purchasing an additional 3,643 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in CVS Health by 2.7% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 43,503 shares of the pharmacy operator’s stock valued at $3,434,000 after purchasing an additional 1,150 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in CVS Health by 6.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 115,101 shares of the pharmacy operator’s stock valued at $9,088,000 after purchasing an additional 6,899 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Up 0.9 %

Shares of NYSE:CVS traded up $0.62 during midday trading on Thursday, hitting $69.22. 5,025,771 shares of the stock were exchanged, compared to its average volume of 10,825,672. The stock has a market capitalization of $87.25 billion, a price-to-earnings ratio of 10.71, a P/E/G ratio of 0.91 and a beta of 0.52. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.86. The business’s 50-day moving average price is $75.53 and its 200 day moving average price is $73.73. CVS Health Co. has a 12 month low of $64.41 and a 12 month high of $83.25.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.11. The company had revenue of $93.81 billion for the quarter, compared to analysts’ expectations of $90.58 billion. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business posted $1.99 earnings per share. Analysts predict that CVS Health Co. will post 8.32 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Monday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.84%. The ex-dividend date is Friday, April 19th. CVS Health’s dividend payout ratio is currently 41.18%.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of research reports. HSBC initiated coverage on CVS Health in a report on Friday, December 22nd. They set a “buy” rating and a $94.00 target price for the company. Royal Bank of Canada dropped their target price on CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a report on Thursday, February 8th. SVB Leerink began coverage on CVS Health in a research report on Monday, February 26th. They issued an “outperform” rating and a $88.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $87.00 price target on shares of CVS Health in a research report on Wednesday, April 10th. Finally, Barclays began coverage on CVS Health in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $78.00 price target on the stock. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $89.44.

Insider Buying and Selling

In related news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $76.95, for a total value of $2,267,947.35. Following the transaction, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at $3,059,916.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.24% of the stock is owned by insiders.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.